Emer­gent reshuf­fles its man­u­fac­tur­ing brain trust as CEO sends mixed mes­sages around Covid-19 vac­cine de­ba­cle

Weeks af­ter Mary­land-based Emer­gent BioSo­lu­tions bun­gled 15 mil­lion dos­es of J&J’s Covid-19 shot and was shut out of its own Bal­ti­more fa­cil­i­ty, the CD­MO is set on shak­ing up its man­u­fac­tur­ing lead­er­ship. Star­ing at a big fi­nan­cial hit from the or­deal, though, Emer­gent still can’t get its sto­ry straight on ex­act­ly what went down with J&J’s shots.

In an earn­ings call with in­vestors Thurs­day, CEO Bob Kramer said a “cross-con­t­a­m­i­na­tion” mix-up of the ade­n­ovirus vec­tors used in the J&J and As­traZeneca shots pro­duced on site was to blame for the J&J shots be­ing thrown out. But that’s not the sto­ry he gave the pub­lic ear­li­er this month. In an in­ter­view with CN­BC on April 1, Kramer said an in­gre­di­ents mix-up wasn’t the is­sue but rather that J&J’s shot batch was sim­ply man­u­fac­tured out-of-spec — which has very dif­fer­ent im­pli­ca­tions in terms of the com­pa­ny’s abil­i­ty to do its job well.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER